SEC For	rm 4 FORM	4		TED ST		S SE	CL	JRIT		ANE	DE	ХСНА	NGE		имі	SSION				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				UNITED STATES SECURITIES AND EXCHANGE COMMISS Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSH Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934														OMB APPROVAL OMB Number: 3235 Estimated average burden hours per response:		3235-0287
Instruc	uon r(b).			FI								mpany Act								
1. Name and Address of Reporting Person <sup>*</sup> Rogers Erica J.						2. Issuer Name <b>and</b> Ticker or Trading Symbol Silk Road Medical Inc [SILK]										Relationship o eck all applic X Director	able) r	)	10% Ow	vner
	Last) (First) (Middle) C/O SILK ROAD MEDICAL, INC. 213 INNSBRUCK DRIVE				01	3. Date of Earliest Transaction (Month/Day/Year) 01/11/2023									X Officer (give title Other (specify below) below) President and CEO					
(Street) SUNNYVALE CA 940				)	_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
Table I - Non-Deriva       1. Title of Security (Instr. 3)     2. Transaction Date (Month/Day/Yet)				on	2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)		4. Di: 5)	(4) or			5. Amount of		ing	6. Ownerst Form: Dire (D) or Indir (I) (Instr. 4)	ct Indirec ect Benefi	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
0	Q41-			01/11/2	0.2.2				Code	V	-		(D)	Price	(1	Instr. 3 and 4)			_	
Common Stock Common Stock				01/11/2023					M <sup>(1)</sup>		┢	6,000 6,000	A D	\$1.6 \$51.5	+	252,199 246,199		D D	_	
Common									5					<b>4</b> 01.0		83,843		I	The	2
			Table	II - Deriv (e.g.,								osed of, convertil				Owned			9	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any			action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)				nd 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Natur of Indirec Beneficia Ownersh (Instr. 4)
					Code	V (A)		(D)	Date Exercisable			Expiration Date	Title	or Nu of	nount mber ares					
Option (right to	\$1.6	01/11/2023			M <sup>(1)</sup>			6,000	09/04/	/2016 <sup>(</sup>	(3)	08/04/2026	Comm Stoc		000	\$0		36,654	D	

Explanation of Responses:

1. The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2022.

2. These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace Rogers Family Trust.

3. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Remarks:

/s/Mhairi Jones, by power of attorney

01/13/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.